Opes Wealth Management LLC Raises Stock Position in Johnson & Johnson $JNJ

Opes Wealth Management LLC increased its stake in Johnson & Johnson (NYSE:JNJ) by 61.6% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 12,169 shares of the company’s stock after purchasing an additional 4,640 shares during the quarter. Opes Wealth Management LLC’s holdings in Johnson & Johnson were worth $1,859,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Smith Group Asset Management LLC boosted its stake in shares of Johnson & Johnson by 1.6% during the 2nd quarter. Smith Group Asset Management LLC now owns 122,823 shares of the company’s stock worth $18,761,000 after acquiring an additional 1,986 shares during the last quarter. FSM Wealth Advisors LLC boosted its stake in shares of Johnson & Johnson by 107.4% during the 2nd quarter. FSM Wealth Advisors LLC now owns 8,453 shares of the company’s stock worth $1,313,000 after acquiring an additional 4,378 shares during the last quarter. Gill Capital Partners LLC boosted its stake in shares of Johnson & Johnson by 4.6% during the 2nd quarter. Gill Capital Partners LLC now owns 2,365 shares of the company’s stock worth $361,000 after acquiring an additional 103 shares during the last quarter. Hoge Financial Services LLC boosted its stake in shares of Johnson & Johnson by 6.3% during the 2nd quarter. Hoge Financial Services LLC now owns 1,381 shares of the company’s stock worth $211,000 after acquiring an additional 82 shares during the last quarter. Finally, Bleakley Financial Group LLC boosted its stake in shares of Johnson & Johnson by 1.4% during the 2nd quarter. Bleakley Financial Group LLC now owns 112,363 shares of the company’s stock worth $17,163,000 after acquiring an additional 1,543 shares during the last quarter. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Stock Performance

Shares of NYSE JNJ opened at $190.38 on Friday. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.76 and a current ratio of 1.07. The company has a market cap of $458.69 billion, a P/E ratio of 18.38, a P/E/G ratio of 2.26 and a beta of 0.40. The firm’s fifty day moving average is $182.26 and its two-hundred day moving average is $166.13. Johnson & Johnson has a 52-week low of $140.68 and a 52-week high of $194.48.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Wednesday, August 30th. The company reported $2.26 earnings per share (EPS) for the quarter. The company had revenue of $24.02 billion for the quarter. Johnson & Johnson had a net margin of 27.26% and a return on equity of 32.73%. As a group, analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 9th. Shareholders of record on Tuesday, November 25th will be issued a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a yield of 2.7%. The ex-dividend date is Tuesday, November 25th. Johnson & Johnson’s payout ratio is currently 50.19%.

Analyst Upgrades and Downgrades

JNJ has been the topic of several analyst reports. The Goldman Sachs Group lifted their price target on shares of Johnson & Johnson from $186.00 to $212.00 and gave the stock a “buy” rating in a research note on Thursday, October 9th. Argus set a $210.00 target price on shares of Johnson & Johnson in a research note on Wednesday, October 15th. Johnson Rice set a $190.00 target price on shares of Johnson & Johnson and gave the company a “hold” rating in a research note on Wednesday. Cowen restated a “buy” rating on shares of Johnson & Johnson in a research note on Tuesday, October 14th. Finally, Guggenheim upgraded shares of Johnson & Johnson from a “neutral” rating to a “buy” rating and lifted their target price for the company from $167.00 to $206.00 in a research note on Tuesday, September 23rd. Three investment analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have assigned a Hold rating to the company. Based on data from MarketBeat.com, Johnson & Johnson presently has an average rating of “Moderate Buy” and a consensus target price of $199.05.

Insider Transactions at Johnson & Johnson

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of Johnson & Johnson stock in a transaction on Thursday, September 4th. The shares were sold at an average price of $177.81, for a total value of $10,041,108.51. Following the sale, the executive vice president directly owned 178,013 shares in the company, valued at approximately $31,652,491.53. The trade was a 24.08% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Corporate insiders own 0.16% of the company’s stock.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.